Pharma giants prioritize profit over public health in obesity drug pricing
Original framing: “Novo CEO Says No Intention to Lower Wegovy Prices Further” — Bloomberg
Low-income and minority communities are disproportionately affected by high drug prices and limited access to healthcare. Their voices are often excluded from pharmaceutical pricing decisions, despite being the most impacted by these policies.
The refusal of Novo Nordisk to lower Wegovy prices is not a business decision but a symptom of a deeper systemic failure in the pharmaceutical industry.
Profit motives are prioritized over public health, with marginalized communities bearing the brunt of high drug costs. Historical parallels and cross-cultural health models reveal alternative pathways, such as public health investment and generic drug production, which can restore balance. Indigenous and artistic perspectives challenge the reductionist view of health as a commodity, while scientific evidence supports non-pharmaceutical interventions. To create a more just health system, we must integrate transparency, public accountability, and diverse health strategies that prioritize human well-being over corporate profit.